NCT03414541View on ClinicalTrials.gov

Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

September 24, 2017

Primary Completion Date

January 11, 2019

Study Completion Date

January 29, 2019

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

DS102

DS102

OTHER

Placebo

Placebo

Trial Locations (3)

Unknown

UK Site 2, Belfast

UK Site 3, London

UK Site 1, Manchester

Sponsors

Lead Sponsor

Afimmune
All Listed Sponsors
lead

Afimmune

INDUSTRY

NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter